RE:RE:RE:RE:Thoughts on pan can deal Noteable, thank you for your link to the video from PanCAN. The recent news about ONC/Y's participation in PanCAN's Precision Promise trail and the subsequent increase in share price and share volume is very gratifying.
I'm very familiar with PanCAN as I recently used their services to search for clinical trials in pancreatic cancer for a close relation. They are very professional and very helpful. I'm pleased that they are an organization that ONC/Y will be doing an adaptive phase 2/3 trial with. The benefits of an adaptive trial with fewer patients, lower costs, and a faster completion are great.
However, I am quite sure that PanCAN will not be paying for the majority of the clinical trial costs. That will be the responsibility of ONC/Y or a partner. That was made clear in the video that Noteable provided the link for. They stated in the video that their total yearly budget in 2022 for clinical trials was a mere $28 million. Also, they said a benefit of the Precision Promise adaptive trials was that it would reduce the costs of the trial to the sponsors of the trial, not eliminate the costs.
Still great news and an unexpected turn of events. Good luck to all!